Discover how Avigen’s avidity-based microfluidic platform resolved inconsistent cytotoxicity data for NK:IO’s Cetuximab-mediated NK cell programme, revealing CD16-dependent target engagement and donor-specific avidity differences that standard endpoint assays could not detect. Download the full case study to learn how paired avidity and functional data identified the optimal NK cell population for Cetuximab-driven ADCC, delivering mechanistic clarity that conventional cytotoxicity assays routinely miss.